STOCK TITAN

Viridian Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced CEO Jonathan Violin, Ph.D., will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, at 8:50 AM EST. He will also participate in fireside chats at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 AM GMT, and the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 10:55 AM EST. The company's lead program, VRDN-001, targets insulin-like growth factor-1 receptor for treating thyroid eye disease (TED), an autoimmune condition that can lead to vision complications.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference and participate in fireside chats at the Jefferies London Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference.

Credit Suisse 30th Annual Healthcare Conference
Format:Corporate Presentation
Date:Monday, November 8, 2021
Time:8:50am EST
  
Jefferies London Healthcare Conference
Format:Fireside Chat
Date:Thursday, November 18, 2021
Time:8:00am GMT
Webcast Link
  
Evercore ISI 4th Annual HealthCONx Conference
Format:Fireside Chat
Date:Wednesday, December 1, 2021
Time:10:55am EST
Webcast Link

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). TED is a debilitating auto immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com

Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com


FAQ

What are the upcoming events for Viridian Therapeutics (VRDN) in November 2021?

Viridian Therapeutics (Nasdaq: VRDN) will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, and participate in the Jefferies London Healthcare Conference on November 18, 2021.

What is VRDN-001 and its significance?

VRDN-001 is a monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R) for treating thyroid eye disease (TED), a serious autoimmune condition.

When is the Evercore ISI HealthCONx Conference for Viridian Therapeutics (VRDN)?

The Evercore ISI 4th Annual HealthCONx Conference for Viridian Therapeutics (Nasdaq: VRDN) is scheduled for December 1, 2021, at 10:55 AM EST.

Who is presenting for Viridian Therapeutics at these conferences?

Jonathan Violin, Ph.D., President and CEO of Viridian Therapeutics, will present at the upcoming conferences.

Viridian Therapeutics, Inc.

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Stock Data

1.74B
76.36M
0.01%
96.04%
12.82%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM